UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 8-K/A

                                 CURRENT REPORT
     Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

         Date of Report (Date of Earliest Event Reported): May 28, 2008

                        Commission File Number 000-52263


                              CAVIT SCIENCES, INC.
             (Exact name of registrant as specified in its charter)

             Florida                                            03-0586935
   (State or Other Jurisdiction                              (I.R.S Employer
of Incorporation or Organization)                         Identification Number)

                      1600 South Dixie Highway, Suite 500,
                           Boca Raton , Florida 33432
                    (Address of principal executive offices)

                                  (561)544-6988
              (Registrant's telephone number, including area code)


                    20 NW 181st Street, Miami, Florida 33169
          Former name or former address, if changed since last report:

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17
    CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
    CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
    Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
    Exchange Act (17 CFR 240.13e-4(c))

ITEM 1.02 TERMINATION OF A MATERIAL DEFINITIVE AGREEMENT

     As previously  reported in the Registrant's  Current Report on Form 8-K, on
May  28,  2008,  the  Registrant   entered  into  an  Asset  Purchase  Agreement
("Agreement") with Alternecare Health Products, Inc. ("Alternecare") pursuant to
which the Registrant agreed to acquire certain inventory, promotional materials,
displays and exhibits, customer lists, existing relationships with manufacturers
and customers,  trademark and website in exchange for 250,000  restricted shares
of the  Registrant's  common  stock and a one-year  promissory  note  payable to
Alternecare in the principal amount of $50,000.

     Inasmuch as SEC  regulations  required the  Registrant to provide pro forma
financial  information  regarding the Registrant and  Alternecare  for two prior
fiscal years,  the  Registrant  made an attempt to have the books and records of
Alternecare  audited.  However, due to the lack of reliable records of inventory
and other  account  activity,  the  Alternecare  audit  could not be  completed.
Consequently,  Alternecare  and the  Registrant  agreed to cancel the  Agreement
effective July 31, 2008. Alternecare delivered the signed cancellation agreement
to the  registrant  on  August  1,  2008.  Alternecare  has  returned  the stock
certificate and promissory note that had been issued to it to the Registrant.

                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto authorized.

Date: August 7, 2008                   Cavit Sciences, Inc.


                                       By: /s/ Colm J. King
                                          --------------------------------------
                                           Colm J. King
                                           President and Chief Executive Officer

                                       2